Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
Amandine Desette, Pierre-Olivier Guichet, Sheik Emambux, Konstantin Masliantsev, Ulrich Cortes, et al.. Deciphering Brain Metastasis Stem Cell Properties From Colorectal Cancer Highlights Specific Stemness Signature and Shared Molecular Features. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16 (5), pp.757-782. ⟨10.1016/j.jcmgh.2023.07.008⟩. ⟨hal-04302791⟩
Mots clés
Dabrafenib
Immunotherapy
Colorectal cancer
2-chlorodeoxyadenosine
Chemotherapy
Adjuvant FOLFOX
Abdominal pain
Acute generalized exanthematous pustulosis
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Surgical excision
Brain Metastases
Biomarker
Metastatic
Locally advanced
Sonic Hedgehog
Adjuvant
BRAF V600E
ALK rearrangement
Anti-PD-1
Follow-up
Anti-CTLA-4
BRAFV600E
Antibody-drug conjugate
Anti-PD-1 antibody
Colon cancer
Cemiplimab
Allelic imbalance
Plasma
Metastatic cSCC
Adjuvant therapy
Circulating tumor DNA
Osimertinib
AZD9291
Treatment
Invasive cutaneous squamous cell carcinoma
Non-small cell lung cancer
Crizotinib
Lung adenocarcinoma
Molecular targeted therapies
BRAFV600-mutant melanoma
Anti-PD1 blockade
BRAFV600E mutation
Nivolumab
Antineoplastic agents
Safety
ACTH
Prevention
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Gastric bypass
Biliopancreatic diversion
ALK
Trametinib
Circulating cell-free DNA
Prognosis
Radiofrequency ablation
Diagnosis
Cutaneous squamous cell carcinoma
Merkel cell carcinoma
Body mass index
Bariatric surgery
Adverse events
Cancer bronchique non à petites cellules
Anti-PD1
Cancer
Advanced
Bone marrow niche
BRAF
TNM classification
C797S
Anti-Tumor pharmacology
Colorectal carcinoma
Melanoma
Survival
Advanced melanoma
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Langerhans cell histiocytosis
Targeted therapy
Androgen insensitivity
Mesenchymal stromal cells
AML
Beta-catenin
Histiocytosis
Children
Radiotherapy
ADN tumoral circulant
Wnt
Systemic therapy
EGFR
Staging
CARMN
BRAF V600-mutation
Immunohistochemistry
Chemoresistance
Abscopal effect
Prognostic
Immunomodulation
Resistance
Polyomavirus
Biomarkers
Immune checkpoint inhibitor